Obstructive sleep apnoea and obesity by Tintinger, GR et al.
174
Review Article: Obstructive sleep apnoea and obesity
2011;24(4)S Afr J Clin Nutr
Tintinger GR,a Pretorius L,b Labadarios Dc 
aDepartment of Internal Medicine, Steve Biko Academic Hospital, Faculty of Health Sciences
University of Pretoria, Pretoria
bMedical Research Council Unit for Inflammation and Immunity, Department of Immunology
Faculty of Health Sciences, University of Pretoria 
cHuman Sciences Research Council, Population Health
Health Systems and Innovation (PHHSI), Cape Town
Correspondence to: Dr GR Tintinger, e-mail: grtintinger@gmail.com
Keywords: obstructive sleep apnoea and obesity
Obstructive sleep apnoea and obesity
Introduction
Modern society is currently faced with a serious global obesity 
epidemic, which appears particularly prevalent in the USA.1 However, 
obesity is also a major concern in South Africa. Prevalence rates for 
adult men and women, as high as 29% and 57% respectively, have 
been reported.2 
Importantly, children are also becoming obese early in life. The 
obesity epidemic is associated with another serious, unrecognised 
epidemic due to obstructive sleep apnoea (OSA). There is a 
consistent relationship between obesity and OSA, with a body mass 
index (BMI) ≥ 30 kg/m2 having been reported in 60-90% of OSA 
patients. As the prevalence of obesity increases, there is likely to be 
a parallel increase in the prevalence of OSA.3 The prevalence of OSA 
in the adult population is estimated to be about 25%, rising to 45% 
in obese individuals.3 OSA is more common in men and the elderly, 
but can also occur in children and young adults.
Despite the fact that 1 in 4 Americans are considered at high risk 
for OSA, only 10-20% of patients in the USA are diagnosed with 
the condition.4 Worldwide, estimates are far worse, with only one 
per cent of patients with OSA receiving appropriate therapy for their 
disease.
This review will discuss the importance and pathogenesis of OSA, 
describe the links between obesity, inflammation, the metabolic 
syndrome and OSA, as well as focus on diagnostic strategies and 
therapy, including diet and nutrition.
Importance of OSA
OSA is important due to its increasing prevalence worldwide. 
Despite being so common, over 80% of individuals with moderate-
to-severe disease are never diagnosed. A recent study among 
patients with type 2 diabetes in the USA, documented an 86% 
prevalence of undiagnosed OSA.5 The latter is thought to result in the 
progression of OSA and its related complications. OSA is recognised 
as an independent risk factor for hypertension, stroke, myocardial 
infarction, arrhythmias, and cardiovascular events.6 Furthermore, 
OSA is often closely associated with other conditions which are 
recognised causes of morbidity and mortality such as obesity, 
metabolic syndrome, atherosclerosis, systemic inflammation, insulin 
resistance. and type 2 diabetes mellitus.7,8 It has been reported 
that untreated OSA may shorten the lifespan of patients by up to 
20 years.9
OSA also impact. adversely on the quality of life of patients due to 
the symptoms and complications of the disease. OSA may result in 
memory impairment, poor performance at work and an increased 
risk of motor vehicle accidents.10,11
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Healthcare costs are increased significantly as a result of untreated 
OSA. and estimates from the USA report an additional annual cost of 
$3.4 billion attributable to unrecognised and untreated OSA.12 
Pathogenesis
Obstructive sleep apnoea occurs during sleep when the muscles of 
the upper airway relax, resulting in partial (hypopnea) or complete 
(apnoea) obstruction to airflow. This loss of muscle tone leads to a 
collapse of the upper airway during sleep, especially if a predisposing 
factor such as obesity is present.13 Apnoeas and hypopneas are 
especially pronounced in the supine position during REM (dream) 
sleep and result in arousals from sleep, and enhanced respiratory 
effort towards the end of the event. In addition, oxygen saturation 
often falls during, or just after, these events, and is restored when 
activation of the sympathetic system occurs in response to nocturnal 
hypoxia.14 As soon as airflow and oxygenation return to normal, sleep 
usually continues. Recurrent arousals and sympathetic stimulation 
are associated with poor quality sleep as the cycles of obstruction, 
followed by restoration of airflow at the termination of events, 
continues throughout the night, sometimes repeating a number of 
times per hour. The measured episodes of apneas, plus hypopneas, 
per hour, is used to quantify the severity of disease as the apnoea-
hypopnea index (AHI).
Importantly, during the sympathetic activation associated with 
apnoeas, a patient’s blood pressure may reach extremely high levels, 
and many patients with OSA have loss of the normal physiological 
pattern of “nocturnal dipping”.6 Systolic and diastolic blood pressure 
normally decreases during non-REM sleep to rest the cardiovascular 
system. Loss of nocturnal dipping in patients with OSA is associated 
with a poorer outcome and higher cardiovascular risk.15
The aetiology of intermittent upper airway obstruction during sleep 
can be multifactorial, and usually depends on the loss of pharyngeal 
muscle tone in a patient already at risk with a narrow upper airway, or 
crowded oropharynx.13 Although most patients with OSA are obese, 
a significant number have an alternative predisposing factor, such 
as retrognathia, enlarged tonsils, hypothyroidism or a neurological 
condition.
Link to obesity and the metabolic syndrome
The link between obesity, OSA, and the metabolic syndrome has 
been extensively investigated.16 Obesity provides a common 
pathophysiological mechanism for both OSA and the metabolic 
syndrome. Indeed, many patients with OSA and obesity have 
evidence of glucose intolerance, dyslipidaemia, hypertension, 
systemic inflammation or central obesity, all of which are significant 
risk factors for atherosclerosis.17 OSA, even in patients without 
obesity, may cause hypertension, systemic inflammation, and insulin 
Figure 1: An overview of the interactions between obesity, obstructive sleep apnoea (OSA), metabolic syndrome, systemic inflammation and atherosclerosis
OSA is initiated by the mechanical effects of airflow obstruction, which result in hypoxia, inflammation, left ventricular hypertrophy and endothelial dysfunction. Obesity predisposes to both OSA, and the metabolic syndrome, 
and both of these conditions can lead to atherosclerosis, ischaemic heart disease, strokes, and peripheral vascular disease. Patients with additional risk factors such as smoking, or a family history of cardiovascular disease or 
hypertension, are at especially high risk of atherosclerosis and peripheral vascular disease, which increases morbidity and mortality.
176
Review Article: Obstructive sleep apnoea and obesity
2011;24(4)S Afr J Clin Nutr
resistance. The high prevalence of OSA in patients with type 2 
diabetes (86%) renders these patients susceptible to complications 
from both diseases, and places them at high risk of atherosclerosis 
and cardiovascular disease.5 Diabetic patients with OSA may 
experience worsening of their glucose control, which improves when 
the OSA is appropriately treated.18
An additional underlying factor which links obesity, OSA, and the 
metabolic syndrome, is systemic inflammation. Obesity is a systemic 
inflammatory disease, and is associated with low-grade systemic 
inflammation and endothelial dysfunction. Elevated levels of the 
inflammatory marker, C-reactive protein (CRP) have been reported 
in obese individuals. OSA itself further exacerbates systemic 
inflammation in obese patients.19 OSA initiates a cascade of events 
which, although initially mechanical in nature, results in the activation 
of macrophages, which release pro-inflammatory cytokines, namely 
tumour necrosis factor-alpha (TNF-a) and interleukin-1 (IL-1), the so 
called endogenous mediators of inflammation.20 If the OSA remains 
untreated, the cycle of macrophage activation and release of pro-
inflammatory cytokines continues, and a state of para-inflammation 
is established, a setting for ongoing endothelial dysfunction and 
progression of atherosclerosis (Figure 1).20, 21 
A number of markers of systemic inflammation are elevated in 
obese, and non-obese, patients with OSA, including TNF-a, IL-6 and 
CRP. These markers tend to decrease with CPAP therapy, in both 
the obese and lean subjects, suggesting that OSA is at least partly 
responsible for the systemic inflammatory response. 
Interestingly, leptin levels are also increased in patients with 
OSA, especially those with co-morbid obesity, but also in lean 
individuals. Leptin resistance in OSA has been linked to the effects 
of inflammatory cytokines.17 Leptin concentrations tend to decrease 
following therapy for OSA. The systemic nature of OSA is also 
responsible for many of the extra-pulmonary features of the disease 
resulting in multi-organ dysfunction, such as a procoagulant state, 
cardiac failure, atherosclerosis and proteinuria.19
How to recognise OSA
Patients with OSA may complain of symptoms that occur at night, 
such as excessive snoring, gasping or choking sensations during 
sleep, breathing pauses during sleep (witnessed apnoeas), nocturia, 
diaphoresis and poor quality sleep. Although 95% of patients with 
OSA complain of snoring at night, this symptom is not specific to 
OSA.11 Witnessed apnoeas have better diagnostic accuracy than 
snoring, but this symptom is not always present.11
Poor quality sleep, night after night, results in a wide spectrum of 
daytime symptoms. These include excessive daytime sleepiness, 
fatigue, morning headaches, memory impairment, an increased 
tendency to be involved in motor vehicle accidents, personality 
changes and depression, loss of libido, and poor concentration at 
work.11
Central obesity may be present in patients with OSA, and a waist 
circumference > 102 cm correlates with an increased AHI. A useful 
clinical screening tool is the STOP (snoring, tired, observed, pressure) 
Bang (BMI, age, neck circumference, gender) questionnaire (Table I), 
used by anaesthesiologists, which has a sensitivity of 92.9% and 
100%, for detecting moderate and severe OSA, respectively.22
Table I: The STOP Bang screening diagnostic tool
 Symptoms, signs, predisposing factors Yes No
1.  Snoring: Do you snore loudly (loud enough to be heard 
through closed doors)?
2.  Tired: Do you often feel tired, fatigued, or sleepy during 
the daytime?
3.  Observed: Has anyone observed you stop breathing 
during your sleep?
4.  Blood Pressure: Do you have, or are you being treated, 
for high blood pressure?
5.  BMI: BMI > 35 kg/m
2
?
6.  Age: Age > 50 years old?
7.  Neck circumference: neck circumference > 40 cm?
8.  Gender: male?
Interpretation: a positive answer (“Yes”) to three, or more, of these symptoms, means the patient has a 
high risk of OSA.
Patients may also present with OSA complications, such as 
cardiac arrhythmias, including atrial fibrillation, difficult-to-control 
hypertension (drug-resistant hypertension), pulmonary hypertension, 
and congestive heart failure.7 OSA is highly prevalent among patients 
with cardiac failure, and may result in deterioration of cardiac 
function. 
Diagnosis
A high index of suspicion is required by practitioners and dietitians 
or nutritionists to recognise the symptoms of OSA, so that patients 
can be referred for an appropriate diagnostic test. The diagnosis 
of OSA is confirmed by means of an overnight sleep study, or 
polysomnogram (PSG), which measures various parameters, 
including airflow, breathing activity and respiratory effort (Figure 
2), oxygen concentration, brain EEG activity, leg muscle activity, and 
sleeping position. 
The PSG can be performed at a sleep laboratory, or at the patient’s 
home.23 A recent study found that 76% of patients preferred to have 
their sleep study at home, and the available evidence indicates 
that the results of studies performed at home, or in a laboratory 
setting, for the diagnosis of OSA, are equivalent.23 The PSG is used 
to measure the AHI, and to determine the level of CPAP necessary 
to treat the patient. 
Figure 2: A schematic representation of a polysomnogram, showing cessation 
of airflow (apnoea) in the upper tracing, associated with an increased respiratory 
effort at the termination of the apnoeic episode in the lower tracing. This is 
usually associated with a sympathetic response, and a brief arousal from sleep.
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An AHI ≥ 5/hour is diagnostic of OSA, and is considered mild in 
severity if < 15/hour. An index ≥ 15/hour indicates moderate OSA, 
while an AHI ≥ 30/hour represents severe disease. This classification 
is important as it is used to guide subsequent therapy.
Treatment
CPAP is the effective treatment of choice for OSA. CPAP is effective, 
provided patients are able to tolerate the face mask and positive 
pressure.24 Most patients can select a well-fitting nasal mask, and 
often experience such a dramatic change in their quality of life, 
that they become long-term adherers to CPAP. Many patients sleep 
better, and are more awake during the day, able to concentrate, 
and insist on taking their machines whenever they go on holiday. 
However, some patients find it difficult to adapt to the wearing of 
the mask or the potove pressure, and despite all efforts they need 
an alternative form of therapy. This alternative form of treatment 
may include an oral appliance for mild OSA, or surgery for specific 
indications. A lifestyle intervention programme to lose weight can 
also have important benefits. 
Diet and OSA
The high prevalence of obesity in patients with OSA, makes weight 
loss an attractive therapeutic option, and in theory at least, is a 
potentially reversible risk factor. A number of clinical trials have 
been conducted to evaluate the usefulness of dietary restriction in 
patients with OSA, and these have yielded mixed results.3 Some 
weight loss, even of a relatively small amount, can lead to a 
decrease in the patient’s AHI. Although the relationship between the 
amount of weight lost, and the decline in AHI, is not linear, overall, it 
appears that for each kilogramme lost, the AHI decreases by 0.6-1/
hour.25 A reasonable goal is a 10% decrease in body weight, which 
can result in a 26% change in the AHI.26
Untreated OSA patients may have an increased appetite for refined 
carbohydrates, as well as increased ghrelin levels.3 A recent trial 
comparing patients treated with diet alone, CPAP plus diet, and an 
oral appliance plus diet, found that only the group on CPAP therapy 
was able to lose a significant quantity of weight.26 This suggests 
that CPAP therapy may be useful to treat OSA, and facilitate weight 
loss in these patients.26 However, not all studies have shown a 
beneficial effect of CPAP therapy.27
The effects of an intensive lifestyle intervention (ILI) in patients with 
type 2 diabetes with OSA, has also been studied, and compared 
to standard diabetes support and education (DSE).25 Especially 
during the first four months of the trial, patients in the ILI group, 
received portion-controlled diets with an energy content of 1 200-
1 500 kcal/day for those < 113.6 kg, and 1 500-1 800 kcal/day 
for those patients weighing ≥ 113.6 kg. The programme included 
175 minutes/week of moderate intensity exercise activity (brisk 
walking). The DSE group participated in three sessions over a one-
year period, which included discussions on diet and exercise, as 
well as social support. Patients in the ILI group lost significantly 
more weight (10.8 kg), and their AHI decreased by a mean of 5/hour 
(23/hour-18/hour), compared to the DSE group of patients, who did 
not lose weight, and whose AHI increased. This authors concluded 
that an intensive lifestyle intervention protocol can be effective in 
reducing the AHI among obese patients with type 2 diabetes.25
Although the decrease in AHI is usually small, this may be especially 
relevant for overweight patients with mild OSA (AHI 5-14/hour), 
who could potentially be cured if their OSA is due to obesity alone. 
The outlook for obese patients with moderate-to-severe OSA is 
less favourable, with only 5-10% of patients being able to sustain 
a significant weight loss beyond two years.3 However, even small 
changes in weight can have beneficial effects on blood pressure 
and blood glucose control.28 
Conclusion
OSA is a highly prevalent condition associated with obesity, and 
if untreated, is likely to result in serious complications. Effective 
therapy is available for OSA, which, when combined with 
measures such as dietary restriction, blood pressure control, and 
careful attention to reducing risk factors for atherosclerosis, can 
significantly improve the outlook for OSA patients. 
References
1. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation and 
effect of weight loss. Circ. 2006;113(6):898-918.
2. Van der Merwe M-T, Pepper MS. Obesity in South Africa. Obes Rev. 2006;7(4):315-322.
3. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers UK. Interactions between obesity and obstructive 
sleep apnea. Chest. 2010;137(3):711-719.
4. Hiestand DM, Britz P, Goldman M, Phillips B. Prevalence of symptoms and risk of sleep apnea in the US 
population. Chest. 2006;130(3):780-786.
5. Foster GD, Sanders MH, Millman R et al. Obstructive sleep apnea among obese patients with type 2 
diabetes. Diabetes Care. 2009;32(6):1017-1019.
6. Selim B, Won C, Yaggi HK. Cardiovascular consequences of sleep apnea. Clin Chest Med. 
2010;31(2):203-220.
7. Bradley TD, Floras JS. Obstructive sleep apnea and its cardiovascular consequences. Lancet 2009; 
373: 82-93.
8. Malhotra A, Loscalzo J. Sleep and cardiovascular disease: an overview. Prog Cardiovas Dis 2009; 51: 
279-284.
9. Young T, Finn L. Epidemiological insights into the public health burden of sleep disordered breathing: sex 
differences in survival among sleep clinic patients. Thorax 1998; 53: 516-519.
10. Sateia MJ. Neuropsychological impairment and quality of life in obstructive sleep apnea. Clin Chest 
Med 2003; 24: 249-259.
11. McNicholas WT. Diagnosis of obstructive sleep apnea in adults. Proc Am Thorac Soc 2008; 5: 154-160.
12. Kapur V, Blough DK, Sandblom RE et al. The medical cost of undiagnosed sleep apnea. Sleep 1999; 
22: 749-755.
13. Douglas NJ, Polo O. Pathogenesis of obstructive sleep apnea/hypopnea syndrome. Lancet 1994; 344: 
653-655.
14. Yaggi HK, Strohl KP. Adult obstructive sleep apnea/hypopnea syndrome: Definitions, risk factors and 
pathogenesis. Clin Chest Med 2010; 31: 179-186.
15. Del Colle S, Carra R, Rabbia F et al. Hypertension in obstructive sleep apnea. Vascular Disease Prevention 
2005; 2: 29-35.
16. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep 
Med Rev 2005; 9: 221-224.
17. Arnaud C, Dematteis M, Pepin J-L, Baguet J-P, Lévy P. Obstructive sleep apnea, immune-inflammation 
and atherosclerosis. Semin Immunopathol 2009; 31: 113-125.
18. Lui MMS, Ip MSM. Disorders of glucose metabolism in sleep-disordered breathing. Clin Chest Med 
2010; 31: 271-285.
19. Zamarron C, Paz VG, Riveiro A. Obstructive sleep apnea syndrome is a systemic disease. Current 
evidence. Eur J Int Med 2008; 19: 390-398.
20. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
21. Lavie L. Oxidative stress – A unifying paradigm in obstructive sleep apnea and comorbidities. Prog 
Cardiovasc Dis 2009; 51: 300-312.
22. Chung F, Elsaid H. Screening for obstructive sleep apnea before surgery: why is it important? Curr Opin 
Anaesthesiol 2009; 22: 405-411.
23. Skomro RP, Gjevre J, Reid J et al. Outcomes of home-based diagnosis and treatment of obstructive sleep 
apnea. Chest 2010; 138: 257-263.
24. Basner RC. Continuous positive airway pressure for obstructive sleep apnea. NEJM 2007; 356: 
1751-1758.
25. Foster GD, Borradaile KE, Sanders MH et al. A randomized study on the effect of weight loss on obstructive 
sleep apnea among obese patients with type 2 diabetes. Arch Int Med 2009; 169: 1619-1626.
26. Lam B, Sam K, Mok WYK et al. Randomised study of three non-surgical treatments in mild to moderate 
obstructive sleep apnoea. Thorax 2007; 62: 354-359.
27. Kajaste S, Brander PE, Telakivi T et al. A cognitive-behavioral weight reduction program in the treatment 
of obstructive sleep apnea syndrome with or without initial nasal CPAP: a randomized study. Sleep Med 
2004; 5: 125-131.
28. Tuomilehto HPI, Seppä JM, Partinen MM et al. Lifestyle intervention with weight reduction. First-line 
treatment in mild obstructive sleep apnea. Am J Respir Crit care Med 2009; 179: 320-327.
